ArticleEuropean radiology2026
Prediction model to prevent axillary surgery using axillary US and MRI in early breast cancer.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
Abstract
objectivesSentinel lymph node (SLN) biopsy remains the standard for axillary staging in early-stage breast cancer, though ongoing clinical investigations are exploring the omission of axillary procedures in specific subgroups. This study assessed whether axillary ultrasonography (US) and MRI can predict SLN involvement and developed a predictive tool to identify patients who may safely forgo axillary surgery. MATERIALS AND
methodsWe retrospectively analyzed 8114 patients with cT1-T2N0 invasive breast cancer across three cancer centers in China. All patients underwent preoperative axillary US and/or MRI. Multivariate logistic regression identified independent predictors of SLN metastases, which were used to construct a predictive model. The model was validated using a 70:30 training-validation split and visualized through a nomogram. Subgroup analyses evaluated the risk of SLN involvement among patients with negative imaging findings.
resultsSLN metastases were observed in 2545 patients (31.37%), with clinical T2 stage, lymphovascular invasion, Ki-67 ≥ 20%, ER + /HER2- subtype, and positive findings on US or MRI independently associated with SLN involvement (p < 0.001). Among 2282 patients with negative US and MRI findings, the SLN metastasis rate was 16.39%. The multivariable predictive model integrating imaging findings with clinicopathologic variables demonstrated good performance, with an AUC of 0.775 (95% CI: 0.750-0.801) in the training set and 0.759 (95% CI: 0.740-0.778) in the validation set. Notably, omission of axillary surgery would miss nodal metastases in 17.4% of patients eligible for CDK4/6 inhibitors.
conclusionPreoperative US and MRI are valuable for identifying low-risk patients. The prediction model may help select early-stage breast cancer patients for whom axillary surgery can be safely omitted while minimizing undertreatment risks for adjuvant therapies. KEY POINTS: Question Can preoperative axillary ultrasound and MRI reliably stratify lymph node metastasis risk in patients with early-stage breast cancer? Findings A multivariate nomogram developed from 8,114 patients showed consistent predictive accuracy for axillary metastasis (AUC: 0.775 in training; 0.759 in validation cohort). Clinical relevance This model supports individualized axillary management by identifying patients who may safely avoid axillary surgery while preserving accurate nodal risk stratification for adjuvant systemic therapy and radiotherapy decision-making.
Indexed as
Identifiers
41927980What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.